As of 2025-08-09, the Relative Valuation of Tarsus Pharmaceuticals, Inc. (TARS) is (48.40) USD. This relative valuation is based on P/E multiples. With the latest stock price at 47.85 USD, the upside of Tarsus Pharmaceuticals, Inc. based on Relative Valuation is -201.1%.
The range of the Relative Valuation is (46.81) - (46.86) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 17.5x - 18.8x | 18.0x |
| Forward P/E multiples | 18.7x - 22.9x | 20.7x |
| Fair Price | (46.81) - (46.86) | (48.40) |
| Upside | -197.8% - -197.9% | -201.1% |
| Date | P/E |
| 2025-08-08 | -19.15 |
| 2025-08-07 | -19.19 |
| 2025-08-06 | -16.67 |
| 2025-08-05 | -16.47 |
| 2025-08-04 | -16.78 |
| 2025-08-01 | -16.34 |
| 2025-07-31 | -15.54 |
| 2025-07-30 | -16.01 |
| 2025-07-29 | -16.07 |
| 2025-07-28 | -16.71 |
| 2025-07-25 | -16.61 |
| 2025-07-24 | -16.99 |
| 2025-07-23 | -16.90 |
| 2025-07-22 | -16.95 |
| 2025-07-21 | -16.89 |
| 2025-07-18 | -17.31 |
| 2025-07-17 | -16.57 |
| 2025-07-16 | -16.63 |
| 2025-07-15 | -16.24 |
| 2025-07-14 | -16.62 |
| 2025-07-11 | -15.68 |
| 2025-07-10 | -16.48 |
| 2025-07-09 | -16.53 |
| 2025-07-08 | -15.89 |
| 2025-07-07 | -15.98 |
| 2025-07-03 | -16.47 |
| 2025-07-02 | -16.19 |
| 2025-07-01 | -16.01 |
| 2025-06-30 | -16.22 |
| 2025-06-27 | -16.15 |
| 2025-06-26 | -16.14 |
| 2025-06-25 | -16.09 |
| 2025-06-24 | -16.57 |
| 2025-06-23 | -16.25 |
| 2025-06-20 | -16.27 |
| 2025-06-18 | -16.44 |
| 2025-06-17 | -15.78 |
| 2025-06-16 | -16.53 |
| 2025-06-13 | -16.37 |
| 2025-06-12 | -16.39 |
| 2025-06-11 | -16.40 |
| 2025-06-10 | -16.48 |
| 2025-06-09 | -17.26 |
| 2025-06-06 | -17.58 |
| 2025-06-05 | -17.65 |
| 2025-06-04 | -17.07 |
| 2025-06-03 | -17.58 |
| 2025-06-02 | -17.55 |
| 2025-05-30 | -17.19 |
| 2025-05-29 | -17.39 |